ReviewCancers2022
The Biological Roles and Molecular Mechanisms of Long Non-Coding RNA MEG3 in the Hallmarks of Cancer.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Advances in the Molecular Mechanisms of Cholangiocarcinoma: A Comprehensive Review of Biomarkers, Regulatory Pathways and Tumor Microenvironment Reprogramming.International journal of molecular sciences · 2026Review
- lncRNA MEG3 and Beclin-1 as diagnostic biomarkers in serous ovarian carcinoma: molecular and immunohistochemical insights.Journal of molecular histology · 2026Article
- Functional dynamics of lncRNAs and miRNAs in cancer metabolism and neuroinflammation.Molecular biology reports · 2026Review
- MEG3 in glioma stem cells promotes glioblastoma angiogenesis through FUBP3-mediated VGF expression.Clinical and experimental medicine · 2026Article
- Exploring the Role of Long Noncoding RNAs (lncRNAs) as Biomarkers in Cancers.Experientia supplementum (2012) · 2026Review
- Noncoding RNAs: A Novel Frontier in Liver Cancer Research and Therapy: Implications for Precision Oncology.Sub-cellular biochemistry · 2026Review
- Exploring the role of long non-coding RNAs in renal cell carcinoma: insights into signaling pathways.Cancer cell international · 2025Review
- Long non-coding RNAs and VEGF in ovarian cancer: mechanisms and therapeutic potential.Journal of ovarian research · 2025Review
- Role and mechanistic study of long non-coding RNA maternally expressed gene 3 in gastric cancer (Review).Oncology letters · 2025Review
- lncRNA IGFL2-AS1 mediates NSCLC chemoresistance via YBX1-induced HSPA1A/RAP1 activation.Cellular & molecular biology letters · 2025Article
- Diagnostic value of circulating lncRNAs HOTAIR, ANRIL, and MEG3 in oral squamous cell carcinoma and their correlation with clinicopathological features.The journal of liquid biopsy · 2025Article
- Long Non-Coding RNAs: Significant Drivers of Carcinogenesis Mechanisms in Head and Neck Squamous Cell Carcinoma.Current issues in molecular biology · 2025Review
- The Multifaceted Role of p53 in Cancer Molecular Biology: Insights for Precision Diagnosis and Therapeutic Breakthroughs.Biomolecules · 2025Review
- Long noncoding RNA MEG3: an active player in fibrosis.Pharmacological reports : PR · 2025Review
- Deciphering the mysteries of MEG3 LncRNA and its implications in genitourinary cancers.Frontiers in oncology · 2025Review
- Association of long noncoding RNA MEG3 genetic variants with the risk of diabetic neuropathy.International journal of medical sciences · 2025Article
- A Comprehensive Bioinformatic Analysis Identifies a Tumor Suppressor Landscape of the MEG3 lncRNA in Breast Cancer.Indian journal of surgical oncology · 2024Article
- Single-cell analysis uncovers liver susceptibility to pancreatic cancer metastasis via myeloid cell characterization.Discover oncology · 2024Article
- Review
- Ten Hypermethylated lncRNA Genes Are Specifically Involved in the Initiation, Progression, and Lymphatic and Peritoneal Metastasis of Epithelial Ovarian Cancer.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Long non-coding RNAs (lncRNAs) are critical regulators in various biological processes involved in the hallmarks of cancer. Maternally expressed gene 3 (MEG3) is lncRNA that regulates target genes through transcription, translation, post-translational modification, and epigenetic regulation. MEG3 has been known as a tumor suppressor, and its downregulation could be found in various cancers. Furthermore, clinical studies revealed that impaired MEG3 expression is associated with poor prognosis and drug resistance. MEG3 exerts its tumor suppressive effect by suppressing various cancer hallmarks and preventing cells from acquiring cancer-specific characteristics; as it could suppress tumor cells proliferation, invasion, metastasis, and angiogenesis; it also could promote tumor cell death and regulate tumor cell metabolic reprogramming. Hence, MEG3 is a potential prognostic marker, and overexpressing MEG3 might become a potential antitumor therapeutic strategy. Herein, we summarize recent knowledge regarding the role of MEG3 in regulating tumor hallmarks as well as the underlying molecular mechanisms. Furthermore, we also discuss the clinical importance of MEG3, as well as their potential in tumor prognosis and antitumor therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.